Urolithiasis pp 325-328 | Cite as

Differentiation of Unclassified Hypercalciuria Utilizing a Sodium-Cellulose-Phosphate Trial

  • G. M. Preminger
  • R. Peterson
  • C. Y. C. Pak


Proper classification of patients with undifferentiated hypercalciuria has important diagnostic as well as therapeutic implications. However, when undergoing an outpatient evaluation for recurrent stone disease, some patients with hypercalciuric nephrolithiasis may present with elevation of their fasting urinary calcium with no evidence of parathyroid stimulation. This picture of unclassifed hypercalciuria neither fits the description of absorptive hypercalciuria (normal fasting urinary calcium and normal parathyroid function) or renal hypercalciuria (elevated fasting urinary calcium and parathyroid stimulation). In order to further define this group of patients with unclassified hypercalciuria, we utilized a sodium cellulose phosphate (SCP) trial. This test allowed appropriate identification of patients with true absorptive and renal hypercalciuria and uncovered a small subgroup of patients with persistent hypercalciuria and normal parathyroid function.


Outpatient Evaluation Absorptive Hypercalciuria Normal iPTH Hypercalciuric Patient Calcium Calcium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    CYC Pak, F Britton, R Peterson, D Ward, C Northcutt, NA Breslau, M McGuire, K Sakhaee, S Bush, M Nicar, D Norman, and PC Peters, Ambulatory evaluation of nephrolithiasis; classificatioh, clinical presentation and diagnostic criteria, Am. J. Med. 69: 19 (1980).PubMedCrossRefGoogle Scholar
  2. 2.
    CYC Pak, RA Kaplan, and H Bone, A simple test for the diagnosis of absorptive, resorptive, and renal hypercalciurias, NEJM 292: 497 (1975).PubMedCrossRefGoogle Scholar
  3. 3.
    CYC Pak, Medical management of neprolithiasis: Update 1988, J. Urol. In press (1988).Google Scholar
  4. 4.
    FH Shen, DJ Baylink, RL Nielson, DJ Sharrard, JL Ivey, and MR Haussler, Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria, J. Lab. Clin. Med. 90: 955 (1977).PubMedGoogle Scholar
  5. 5.
    AE Broadus, KL Insogna, R Lang, AF Ellison, and BE Dreyer, Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria, NEJM 311: 73 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    AH Tashjian, EF Voelkel, L Levine, and P Goldhaber, Evidence that bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2, J. Expt. Med. 136: 1329 (1972)/CrossRefGoogle Scholar
  7. 7.
    AC Buck, CJ Lote, and WF Sampson, The influence of renal prostaglandings on urinary calcium excretion in idiopathic urolithiasis, J. Urol. 129: 421 (1983).PubMedGoogle Scholar
  8. 8.
    GM Preminger and CYC Pak, Eventueal attenuation of hypocalciuric response to HCTZ in absorptive hypercalciuria, J. Urol. 137: 1104 (1987).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • G. M. Preminger
    • 1
  • R. Peterson
    • 1
  • C. Y. C. Pak
    • 1
  1. 1.Center for Mineral Metabolism and Clinical Research and Division of Urology, Department of SurgeryThe University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations